Login / Signup

Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study.

Clifton O BinghamShawn BlackNatalie J ShiffStephen XuWayne LangholffJeffrey R Curtis
Published in: Rheumatology and therapy (2023)
NCT02728934.
Keyphrases
  • rheumatoid arthritis patients
  • disease activity
  • ulcerative colitis
  • ankylosing spondylitis
  • high dose
  • rheumatoid arthritis
  • cross sectional
  • patient reported outcomes
  • combination therapy
  • low dose
  • smoking cessation